NCT01833754View on ClinicalTrials.gov

Study of Romosozumab (AMG 785) Administered to Healthy Participants and Patients With Stage 4 Renal Impairment or Stage 5 Renal Impairment Requiring Hemodialysis

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 22, 2013

Primary Completion Date

February 19, 2014

Study Completion Date

February 19, 2014

Conditions
Osteoporosis
Interventions
DRUG

Romosozumab

Administered as three 70 mg/mL prefilled syringe injections

Trial Locations (5)

29118

Research Site, Orangeburg

33028

Research Site, Pembroke Pines

80230

Research Site, Denver

85284

Research Site, Tempe

90022

Research Site, Los Angeles

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY